274 related articles for article (PubMed ID: 30643016)
1. Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF/KRAS Are Enriched for Targetable Kinase Fusions.
Cocco E; Benhamida J; Middha S; Zehir A; Mullaney K; Shia J; Yaeger R; Zhang L; Wong D; Villafania L; Nafa K; Scaltriti M; Drilon A; Saltz L; Schram AM; Stadler ZK; Hyman DM; Benayed R; Ladanyi M; Hechtman JF
Cancer Res; 2019 Mar; 79(6):1047-1053. PubMed ID: 30643016
[TBL] [Abstract][Full Text] [Related]
2. MSI-High RAS-BRAF wild-type colorectal adenocarcinomas with MLH1 loss have a high frequency of targetable oncogenic gene fusions whose diagnoses are feasible using methods easy-to-implement in pathology laboratories.
Bocciarelli C; Caumont C; Samaison L; Cariou M; Aline-Fardin A; Doucet L; Roudié J; Terris B; Merlio JP; Marcorelles P; Cappellen D; Uguen A
Hum Pathol; 2021 Aug; 114():99-109. PubMed ID: 34019865
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive analysis of oncogenic fusions in mismatch repair deficient colorectal carcinomas by sequential DNA and RNA next generation sequencing.
Wang J; Li R; Li J; Yi Y; Liu X; Chen J; Zhang H; Lu J; Li C; Wu H; Liang Z
J Transl Med; 2021 Oct; 19(1):433. PubMed ID: 34657620
[TBL] [Abstract][Full Text] [Related]
4. Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions.
Singh H; Li YY; Spurr LF; Shinagare AB; Abhyankar R; Reilly E; Brais LK; Nag A; Ducar MD; Thorner AR; Shapiro GI; Keller RB; Siletti C; Clark JW; Farago AF; Lin JJ; Demetri GD; Gujrathi R; Kulke MH; MacConaill LE; Ligon AH; Sicinska E; Meyerson ML; Meyerhardt JA; Cherniack AD; Wolpin BM; Ng K; Giannakis M; Hornick JL; Cleary JM
Clin Cancer Res; 2021 Mar; 27(6):1695-1705. PubMed ID: 33414136
[TBL] [Abstract][Full Text] [Related]
5. Rational testing for gene fusion in colorectal cancer: MSI and RAS-BRAF wild-type metastatic colorectal cancer as target population for systematic screening.
Delaye M; Ibadioune S; Julié C; Marin C; Peschaud F; Lupinacci R; Vacher S; Ahmanache L; Antonio S; Schnitzler A; Buecher B; Mariani P; Allory Y; Grati OT; Emile JF; Neuzillet C; Bièche I
Eur J Cancer; 2022 Jul; 170():85-90. PubMed ID: 35598360
[TBL] [Abstract][Full Text] [Related]
6. Microsatellite Instability-High Endometrial Cancers with MLH1 Promoter Hypermethylation Have Distinct Molecular and Clinical Profiles.
Manning-Geist BL; Liu YL; Devereaux KA; Paula ADC; Zhou QC; Ma W; Selenica P; Ceyhan-Birsoy O; Moukarzel LA; Hoang T; Gordhandas S; Rubinstein MM; Friedman CF; Aghajanian C; Abu-Rustum NR; Stadler ZK; Reis-Filho JS; Iasonos A; Zamarin D; Ellenson LH; Lakhman Y; Mandelker DL; Weigelt B
Clin Cancer Res; 2022 Oct; 28(19):4302-4311. PubMed ID: 35849120
[TBL] [Abstract][Full Text] [Related]
7. BRAFV600E immunohistochemistry facilitates universal screening of colorectal cancers for Lynch syndrome.
Toon CW; Walsh MD; Chou A; Capper D; Clarkson A; Sioson L; Clarke S; Mead S; Walters RJ; Clendenning M; Rosty C; Young JP; Win AK; Hopper JL; Crook A; von Deimling A; Jenkins MA; Buchanan DD; Gill AJ
Am J Surg Pathol; 2013 Oct; 37(10):1592-602. PubMed ID: 23797718
[TBL] [Abstract][Full Text] [Related]
8. Microsatellite instability-high colorectal cancer patient-derived xenograft models for cancer immunity research.
Suto H; Funakoshi Y; Nagatani Y; Imamura Y; Toyoda M; Kiyota N; Matsumoto H; Tanaka S; Takai R; Hasegawa H; Yamashita K; Matsuda T; Kakeji Y; Minami H
J Cancer Res Ther; 2021; 17(6):1358-1369. PubMed ID: 34916366
[TBL] [Abstract][Full Text] [Related]
9. BRAF Mutations Are Associated with Poor Survival Outcomes in Advanced-stage Mismatch Repair-deficient/Microsatellite High Colorectal Cancer.
Tan E; Whiting J; Xie H; Imanirad I; Carballido E; Felder S; Frakes J; Mo Q; Walko C; Permuth JB; Sommerer K; Kim R; Anaya DA; Fleming JB; Sahin IH
Oncologist; 2022 Mar; 27(3):191-197. PubMed ID: 35274712
[TBL] [Abstract][Full Text] [Related]
10. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer.
Xiao J; Li W; Huang Y; Huang M; Li S; Zhai X; Zhao J; Gao C; Xie W; Qin H; Cai S; Bai Y; Lan P; Zou Y
BMC Cancer; 2021 Mar; 21(1):282. PubMed ID: 33726687
[TBL] [Abstract][Full Text] [Related]
11. Mismatch Repair (MMR) Gene Alteration and BRAF V600E Mutation Are Potential Predictive Biomarkers of Immune Checkpoint Inhibitors in MMR-Deficient Colorectal Cancer.
Sahin IH; Goyal S; Pumpalova Y; Sonbol MB; Das S; Haraldsdottir S; Ahn D; Ciombor KK; Chen Z; Draper A; Berlin J; Bekaii-Saab T; Lesinski GB; El-Rayes BF; Wu C
Oncologist; 2021 Aug; 26(8):668-675. PubMed ID: 33631043
[TBL] [Abstract][Full Text] [Related]
12. Gene fusions and oncogenic mutations in MLH1 deficient and BRAFV600E wild-type colorectal cancers.
Ukkola I; Nummela P; Kero M; Tammio H; Tuominen J; Kairisto V; Kallajoki M; Haglund C; Peltomäki P; Kytölä S; Ristimäki A
Virchows Arch; 2022 Apr; 480(4):807-817. PubMed ID: 35237889
[TBL] [Abstract][Full Text] [Related]
13. Nuclear translocation of ATG5 induces DNA mismatch repair deficiency (MMR-D)/microsatellite instability (MSI) via interacting with Mis18α in colorectal cancer.
Sun SY; Hu XT; Yu XF; Zhang YY; Liu XH; Liu YH; Wu SH; Li YY; Cui SX; Qu XJ
Br J Pharmacol; 2021 Jun; 178(11):2351-2369. PubMed ID: 33645631
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological and molecular characterization of deficient mismatch repair colorectal cancer.
Yamada A; Yamamoto Y; Minamiguchi S; Kamada M; Sunami T; Ohashi S; Seno H; Kawada K; Muto M
Hum Pathol; 2022 Dec; 130():1-9. PubMed ID: 36150551
[TBL] [Abstract][Full Text] [Related]
15. Variation in KRAS/NRAS/BRAF-Mutation Status by Age, Sex, and Race/Ethnicity Among a Large Cohort of Patients with Metastatic Colorectal Cancer (mCRC).
Booker BD; Markt SC; Schumacher FR; Rose J; Cooper G; Selfridge JE; Koroukian SM
J Gastrointest Cancer; 2024 Mar; 55(1):237-246. PubMed ID: 37355486
[TBL] [Abstract][Full Text] [Related]
16. NTRK oncogenic fusions are exclusively associated with the serrated neoplasia pathway in the colorectum and begin to occur in sessile serrated lesions.
Kim JH; Hong JH; Choi YL; Lee JA; Seo MK; Lee MS; An SB; Sung MJ; Cho NY; Kim SS; Shin YK; Kim S; Kang GH
J Pathol; 2021 Dec; 255(4):399-411. PubMed ID: 34402529
[TBL] [Abstract][Full Text] [Related]
17. ARID1A genomic alterations driving microsatellite instability through somatic MLH1 methylation with response to immunotherapy in metastatic lung adenocarcinoma: a case report.
Durán M; Faull I; Lastra E; Laes JF; Rodrigo AB; Sánchez-Escribano R
J Med Case Rep; 2021 Feb; 15(1):89. PubMed ID: 33608032
[TBL] [Abstract][Full Text] [Related]
18. BRAF V600E/RAS Mutations and Lynch Syndrome in Patients With MSI-H/dMMR Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors.
Colle R; Lonardi S; Cachanado M; Overman MJ; Elez E; Fakih M; Corti F; Jayachandran P; Svrcek M; Dardenne A; Cervantes B; Duval A; Cohen R; Pietrantonio F; André T
Oncologist; 2023 Sep; 28(9):771-779. PubMed ID: 37023721
[TBL] [Abstract][Full Text] [Related]
19. Impact of Institutional Universal Microsatellite-Instability (MSI) Reflex Testing on Molecular Profiling Differences Between Younger and Older Patients with Colorectal Cancer.
Altshuler E; Franke AJ; Skelton WP; Feely M; Wang Y; Lee JH; Read T; Terracina K; Lou XY; Dai Y; George TJ
Clin Colorectal Cancer; 2023 Mar; 22(1):153-159. PubMed ID: 36319582
[TBL] [Abstract][Full Text] [Related]
20. Fusobacterium nucleatum Load Correlates with KRAS Mutation and Sessile Serrated Pathogenesis in Colorectal Adenocarcinoma.
Takeda K; Koi M; Okita Y; Sajibu S; Keku TO; Carethers JM
Cancer Res Commun; 2023 Sep; 3(9):1940-1951. PubMed ID: 37772997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
